Related Experiment Video
Updated: Jul 18, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Advances in the Pathogenesis and Treatment of Resistant Hypertension
Jill Dybiec1, Julia Krzemińska1, Ewa Radzioch1
1Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Łódź, Poland.
Abstract:
Hypertension is a prevalent chronic disease associated with an increased risk of cardiovascular (CV) premature death, and its severe form manifests as resistant hypertension (RH). The accurate prevalence of resistant hypertension is difficult to determine due to the discrepancy in data from various populations, but according to recent publications, it ranges from 6% to 18% in hypertensive patients. However, a comprehensive understanding of the pathogenesis and treatment of RH is essential. This review emphasizes the importance of identifying the causes of treatment resistance in antihypertensive therapy and highlights the utilization of appropriate diagnostic methods. We discussed innovative therapies such as autonomic neuromodulation techniques like renal denervation (RDN) and carotid baroreceptor stimulation, along with invasive interventions such as arteriovenous anastomosis as potential approaches to support patients with inadequate medical treatment and enhance outcomes in RH.
Related Concept Videos
Hypertension II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure V: Medical Management
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension and Regulation of Blood Pressure

